These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33630226)

  • 1. A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography.
    Bando R; Otsuka H; Otani T; Matsuda N; Azane S; Kunikane Y; Otomi Y; Sako W; Izumi Y; Harada M
    Ann Nucl Med; 2021 Apr; 35(4):504-513. PubMed ID: 33630226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan).
    Wakabayashi Y; Takahashi R; Kanda T; Zeng F; Nogami M; Ishii K; Murakami T
    Neurol Sci; 2018 Aug; 39(8):1401-1407. PubMed ID: 29748936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basic Evaluation of Standardized Uptake Value Using SPECT Single Unit to Compare with Specific Binding Ratio in Dopamine Transporter Scintigraphy].
    Sato T; Hayashi M
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2018; 74(10):1129-1137. PubMed ID: 30344209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of the Each Correction Method for the Specific Binding Ratio and Standardized Uptake Value in the Dopamine Transporter SPECT].
    Shiokawa A; Onoguchi M; Shibutani T; Maeda Y; Yoneyama H; Konishi T; Wakabayashi H
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2019; 75(7):638-645. PubMed ID: 31327774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiquantitative analysis using standardized uptake value in
    Toriihara A; Daisaki H; Yamaguchi A; Kobayashi M; Furukawa S; Yoshida K; Isogai J; Tateishi U
    Clin Imaging; 2018; 52():57-61. PubMed ID: 29909364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation.
    Iwabuchi Y; Nakahara T; Kameyama M; Yamada Y; Hashimoto M; Ogata Y; Matsusaka Y; Katagiri M; Itoh K; Osada T; Ito D; Tabuchi H; Jinzaki M
    Ann Nucl Med; 2018 Jun; 32(5):363-371. PubMed ID: 29654576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined visual and semi-quantitative assessment of
    Ueda J; Yoshimura H; Shimizu K; Hino M; Kohara N
    Neurol Sci; 2017 Jul; 38(7):1187-1191. PubMed ID: 28389938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of dopamine transporter imaging (DAT-SPECT) and
    Yoshii F; Ryo M; Baba Y; Koide T; Hashimoto J
    J Neurol Sci; 2017 Apr; 375():80-85. PubMed ID: 28320195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
    Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
    Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count.
    Mizumura S; Nishikawa K; Murata A; Yoshimura K; Ishii N; Kokubo T; Morooka M; Kajiyama A; Terahara A
    Ann Nucl Med; 2018 May; 32(4):288-296. PubMed ID: 29546633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
    Ikeda K; Yanagihashi M; Miura K; Ishikawa Y; Hirayama T; Takazawa T; Kano O; Kawabe K; Mizumura N; Iwasaki Y
    J Neurol Sci; 2018 Aug; 391():5-9. PubMed ID: 30103971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receiver-operating-characteristic analysis of an automated program for analyzing striatal uptake of 123I-ioflupane SPECT images: calibration using visual reads.
    Kuo PH; Avery R; Krupinski E; Lei H; Bauer A; Sherman S; McMillan N; Seibyl J; Zubal G
    J Nucl Med Technol; 2013 Mar; 41(1):26-31. PubMed ID: 23401604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification evaluation of
    Huang K; Feng Y; Liu D; Liang W; Li L
    Ann Nucl Med; 2020 Feb; 34(2):136-143. PubMed ID: 31768820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis.
    Rahman MGM; Islam MM; Tsujikawa T; Kiyono Y; Okazawa H
    Ann Nucl Med; 2019 Jan; 33(1):14-21. PubMed ID: 30276622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes.
    Goto R; Kurihara M; Kameyama M; Komatsu H; Higashino M; Hatano K; Ihara R; Higashihara M; Nishina Y; Matsubara T; Kanemaru K; Saito Y; Murayama S; Iwata A
    J Neural Transm (Vienna); 2023 Apr; 130(4):513-520. PubMed ID: 36871130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index.
    Sakamoto F; Shiraishi S; Ogasawara K; Tsuda N; Nakagawa M; Tomiguchi S; Yamashita Y
    Ann Nucl Med; 2020 Jun; 34(6):415-423. PubMed ID: 32301068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
    Takahashi H; Kashiwagi N; Arisawa A; Matsuo C; Kato H; Adachi H; Kajiyama Y; Mochizuki H; Tomiyama N
    Br J Radiol; 2022 Feb; 95(1130):20210837. PubMed ID: 34808066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT.
    Yokoyama K; Imabayashi E; Sumida K; Sone D; Kimura Y; Sato N; Mukai Y; Murata M; Matsuda H
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):366-372. PubMed ID: 27544223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.